Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 4/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.39 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12396192 | 0.92 | CCR3 (0.45) | HTR2ACYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL12396172 | 0.90 | CCR3 (0.48) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL12396174 | 0.89 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL12396173 | 0.89 | CCR3 (0.48) | HTR2ACYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL12396176 | 0.89 | CYP1A2 (0.40) | HTR2ACYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL12396162 | 0.85 | OPRD1 (0.47) | EPHX1HTR2ACCR3MCHR1DRD2 | |
| SCHEMBL12396169 | 0.84 | CCR3 (0.43) | EPHX1HTR2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12396138 | 0.83 | CCR3 (0.44) | HTR2ACYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL12396167 | 0.83 | CCR3 (0.44) | EPHX1HTR2ACYP2D6CCR3OPRM1 | |
| SCHEMBL12396180 | 0.82 | FPR2 (0.43) | EPHX1HTR2ACYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183358-A1 | METHODS AND COMPOSITIONS FOR DEREPRESSION OF IAP-INHIBITED CASPASE | THE BURNHAM INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20090043099-A1 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2009-02-12 | — | — | US | disclosed |
| US-7217688-B2 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217688-B2 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | EPHX1 3115/4885HTR2A 3132/4885CYP1A2 4466/4885 |
| US-20090043099-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | EPHX1 3115/4885HTR2A 3132/4885CYP1A2 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.